Zhengying Pan
Overview
Explore the profile of Zhengying Pan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1357
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weng W, Zhang P, Pan Z
J Am Chem Soc
. 2024 Oct;
146(42):28717-28727.
PMID: 39388725
Naturally, kinases exert their activities in a highly regulated fashion. A number of ingenious approaches have been developed to artificially control kinase activity by external stimuli, such as the incorporation...
2.
Weng W, Xue G, Pan Z
Eur J Med Chem
. 2023 Dec;
265:116062.
PMID: 38128235
Photocaged proteolysis-targeting chimeras (PROTACs), which employ light as a stimulus to control protein degradation, have recently garnered considerable attention as both powerful chemical tools and a promising therapeutic strategy. However,...
3.
Zheng C, Li W, Ali T, Peng Z, Liu J, Pan Z, et al.
J Neuroimmune Pharmacol
. 2023 Jun;
18(3):383-396.
PMID: 37326908
Amyotrophic lateral sclerosis (ALS) is a fatal multisystem degenerative disorder with minimal available therapeutic. However, some recent studies showed promising results of immunological-based treatment. Here, we aimed to evaluate the...
4.
Fu T, Zuo Y, Xue G, Zhou D, Pan Z
Eur J Med Chem
. 2023 May;
256:115460.
PMID: 37163946
B-lymphoid tyrosine kinase (BLK) is an important knot of B cell receptor signaling, and regulates the function and development of B cells subset. Dysfunction of BLK is correlated with autoimmune...
5.
Zhou D, Zuo Y, Pan Z
J Med Chem
. 2023 Mar;
66(7):4979-4998.
PMID: 36959108
Interleukin-2-inducible T-cell kinase (ITK) is a promising therapeutic target for human autoimmune diseases and T-cell malignant lymphomas. This paper reports the development of a series of cereblon-recruiting ITK proteolysis targeting...
6.
Hao C, Li X, Wang Z, Liu L, He F, Pan Z
Eur J Med Chem
. 2023 Mar;
251:115236.
PMID: 36924668
Mitogen-activated protein kinase kinases 1/2 (MEK1/2) play critical roles in the canonical RAS/RAF/MEK/ERK pathway. Highly selective and potent non-ATP-competitive allosteric MEK1/2 inhibitors have been developed, and three of them were...
7.
Backus K, Pan Z, Jones L
RSC Med Chem
. 2022 Sep;
13(8):893-894.
PMID: 36092145
Guest editors Keriann Backus, Zhengying Pan and Lyn Jones introduce the themed collection on Covalent Drug Discovery.
8.
Zhong Z, Shi L, Fu T, Huang J, Pan Z
J Med Chem
. 2022 May;
65(10):7278-7295.
PMID: 35549181
Fibroblast growth factor receptor 4 (FGFR4) has been identified as a potential target for the treatment of hepatocellular carcinoma (HCC) with aberrant FGFR4 signaling because of its important role in...
9.
Chen R, Wang Z, Liu L, Pan Z
Chem Commun (Camb)
. 2022 Mar;
58(31):4901-4904.
PMID: 35352729
Although extracellular regulated protein kinases (ERKs) are considered important targets for the treatment of various cancers, the occurrence of severe side effects in clinical trials restricts the development of ERK...
10.
Yang J, Liu Z, Perrett S, Zhang H, Pan Z
Bioorg Med Chem Lett
. 2022 Jan;
60:128553.
PMID: 35051576
PES (2-phenylethynesulfonamide, pifithrin-μ, PFTμ) is an electrophilic compound that exhibits anticancer properties, protects against chemotherapy-induced peripheral neuropathy in chemotherapy, and shows immunomodulatory, anti-inflammatory and anti-viral activities. PES generally shows higher...